During the past decade, Nemocnice Jihlava conducted 21 clinical trials. In the 10-year time frame, 21 clinical trials started and 12 clinical trials were completed, i.e. on average, 57.1% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 8 clinical trials were completed. i.e. 114.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Nemocnice Jihlava" #1 sponsor was "Hoffmann-La Roche" with 3 trials, followed by "Biogen" with 2 trials sponsored, "Boehringer Ingelheim" with 2 trials sponsored, "Ferring Pharmaceuticals" with 2 trials sponsored and "Jazz Pharmaceuticals" with 2 trials sponsored. Other sponsors include 17 different institutions and companies that sponsored additional 26 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Nemocnice Jihlava" #1 collaborator was "ADIR, a Servier Group company" with 1 trials as a collaborator, "Association for Functional Rehabilitation, Recreation and Applied Kinesiology Impulse" with 1 trials as a collaborator, "Centre Hospitalier Universitaire de Besancon" with 1 trials as a collaborator, "Charite University, Berlin, Germany" with 1 trials as a collaborator and "Eisai Limited" with 1 trials as a collaborator. Other collaborators include 9 different institutions and companies that were collaborators in the rest 19 trials.

According to Clinical.Site data, the most researched conditions in "Nemocnice Jihlava" are "Multiple Sclerosis" (7 trials), "Breast Cancer" (2 trials), "Psoriasis" (2 trials), "Rheumatoid Arthritis" (2 trials) and "Atrial Fibrillation" (1 trials). Many other conditions were trialed in "Nemocnice Jihlava" in a lesser frequency.

Most popular intervention types in "Nemocnice Jihlava" are "Drug" (26 trials), "Other" (3 trials), "Device" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Mavenclad®" (2 trials), "5% dextrose in water" (1 trials), "ART621" (1 trials) and "ASA 100 mg" (1 trials). Other intervention names were less common.

The vast majority of trials in "Nemocnice Jihlava" are 30 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Nemocnice Jihlava". undefined are not yet recruiting, 2 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 20 completed trials in Nemocnice Jihlava, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Nemocnice Jihlava, 0 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 2 trials that are defined as “Not Applicable".

Nemocnice Jihlava has several departments that took part in Clinical trials: "Nemocnice Jihlava; NEU-Neurologicke oddeleni" - 5 trials, "Pediatricke odd. Nemocnice Jihlava" - 2 trials